Kidney Week

Abstract: FR-PO1208

Reverse Epidemiology and the Obesity Paradox for Patients with CKD

Session Information

• Transplantation: Clinical - Immunosuppression, Adherence, Outcomes
  November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Transplantation

• 1902 Transplantation: Clinical

Authors

• Choudhury, Rashikh A., University of Colorado Hospital, Denver, Colorado, United States

Rashikh A. Choudhury,

• Yoeli, Dor, University of Colorado Hospital, Denver, Colorado, United States

Dor Yoeli,

• Moore, Hunter B., University of Colorado Hospital, Denver, Colorado, United States

Hunter B. Moore,

• Hoeltzel, Gerard, University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States

Gerard Hoeltzel,

• Dumon, Kristoffel R., University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States

Kristoffel R. Dumon,

• Abt, Peter L., University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States

Peter L. Abt,

• Conzen, Kendra D., University of Colorado Hospital, Denver, Colorado, United States

Kendra D. Conzen,

• Nydam, Trevor, University of Colorado Hospital, Denver, Colorado, United States

Trevor Nydam,

Background

Obesity has been associated with both increased progression of chronic kidney disease as well as with a paradoxical improvement in survival among ESRD patients undergoing hemodialysis. As such, the optimal weight management strategy for obese CKD patients remains unclear.

Methods

A decision analytic Markov state transition model was created to simulate the life of 30,000 obese patients with CKD stage 3b, as they progressed to ESRD, transplantation, and death. Life expectancy following conservative medical weight management (observation), Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG) were estimated. Base case patients were defined as being 55 years old and having a pre-intervention BMI of 40 kg/m². Sensitivity analysis of initial BMI was performed. All Markov parameters were extracted from literature review.

Results

RYGB and SG were associated with improved survival for patients with pre-intervention BMI of > 39.6 kg/m². Compared to conservative weight management, base case patients who underwent RYGB gained 10.3 months of life, and gained 8.2 months of life following SG.

Conclusion

Balancing progression of CKD with improved survival on ESRD for obese patients requires selective use of weight management strategies. RYGB and SG improved survival for CKD patients with Class III obesity, but not for patients with Class I and Class II obesity. As such aggressive weight loss interventions should be reserved for patients with Class III obesity, while more conservative methods should be offered to those with Class I and II obesity.